Paper38770366
Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.
Chavalertsakul K and 6 others. Int J Gen Med, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study. Papers, record 38770366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38770366
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29891600 | Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29891600 | PubMed |
| 2 | 34040117 | The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. | Sci Rep | 2021 | https://conductscience.org/library/papers/34040117 | PubMed |
| 3 | 37589788 | Remdesivir: A Review in COVID-19. | Drugs | 2023 | https://conductscience.org/library/papers/37589788 | PubMed |
| 4 | 36776761 | Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand. | Lancet Reg Health Southeast Asia | 2023 | https://conductscience.org/library/papers/36776761 | PubMed |
| 5 | 32423584 | Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. | Lancet | 2020 | https://conductscience.org/library/papers/32423584 | PubMed |
| 6 | 34937145 | Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34937145 | PubMed |
| 7 | 37556727 | Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice. | Clin Infect Dis | 2023 | https://conductscience.org/library/papers/37556727 | PubMed |
| 8 | 33306283 | Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33306283 | PubMed |
| 9 | 35474740 | Antiviral agents for the treatment of COVID-19: Progress and challenges. | Cell Rep Med | 2022 | https://conductscience.org/library/papers/35474740 | PubMed |
| 10 | 36635036 | Inter-rater reliability and prognostic value of baseline Radiographic Assessment of Lung Edema (RALE) scores in observational cohort studies of inpatients with COVID-19. | BMJ Open | 2023 | https://conductscience.org/library/papers/36635036 | PubMed |
| 11 | 35639525 | Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. | J Infect Dis | 2022 | https://conductscience.org/library/papers/35639525 | PubMed |
| 12 | 22446091 | Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. | Bioorg Med Chem Lett | 2012 | https://conductscience.org/library/papers/22446091 | PubMed |
| 13 | 35308532 | Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35308532 | PubMed |
| 14 | 36528039 | Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. | Lancet Respir Med | 2023 | https://conductscience.org/library/papers/36528039 | PubMed |
| 15 | 32445440 | Remdesivir for the Treatment of Covid-19 - Final Report. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32445440 | PubMed |
| 16 | 32284326 | Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. | J Biol Chem | 2020 | https://conductscience.org/library/papers/32284326 | PubMed |
| 17 | 33264556 | Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33264556 | PubMed |
| 18 | 35740211 | Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35740211 | PubMed |
| 19 | 21330339 | Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. | Am J Epidemiol | 2011 | https://conductscience.org/library/papers/21330339 | PubMed |
| 20 | 35396659 | WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. | J Gen Intern Med | 2022 | https://conductscience.org/library/papers/35396659 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40465794 | In-hospital mortality outcomes of favipiravir in patients with moderate to severe COVID-19 infection: An emulated target trial using real-world data from the largest field hospital in Thailand. | PLoS One | 2025 | https://conductscience.org/library/papers/40465794 | PubMed |
| 38770366 | Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study. | Int J Gen Med | 2024 | https://conductscience.org/library/papers/38770366 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38770366
GET https://conductscience.org/api/papers/v1/38770366/references?page=2